Key Insights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 90/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed with results

Key Signals

4Total

P 1 (3)

P 4 (1)

Withdrawn2

Recruiting1

Terminated1

Clinical Trials (4)

Showing 4 of 4 trials

Stem Cells for the Treatment of Pouchitis

Study of Ossium Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in the Setting of Crohn's Disease

Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in Crohn's

Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch

Showing all 4 trials